BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Bio NC

  G1 Therapeutics Added to Nasdaq Biotechnology Index

  G1 Therapeutics today announced that it has been selected for addition to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 18, 2017.

  December 18, 2017

   · 

  2 min read
• Biotech Bay

  Marrone Bio Innovations Announces Comprehensive Financing and Debt Restructuring Transaction

  Under the terms of the Purchase Agreement, the Buyers have agreed to purchase an aggregate of $30M of units, inclusive of funds being advanced by an affiliate of Ospraie as bridge financing under a convertible promissory note.

  December 18, 2017

   · 

  11 min read
• Genetown

  Deciphera Pharma Added to Russell 2000 Index

  Deciphera Pharma today announced that it has been added to the Russell 2000® Index, as part of Russell’s quarterly IPO additions, effective Friday, December 15, 2017, after market close.

  December 18, 2017

   · 

  1 min read
• Policy

  Sanofi and Alnylam Submit Marketing Authorization Application to the EMA for Patisiran for the Treatment of Hereditary ATTR Amyloidosis

  Sanofi Genzyme and Alnylam Pharma announced today the submission of a MAA to EMA for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis.

  December 18, 2017

   · 

  8 min read
• Biotech Beach

  Kura Oncology Added to Nasdaq Biotechnology Index

  Kura Oncology today announced that it has been selected for addition to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 18, 2017.

  December 18, 2017

   · 

  1 min read
• Drug Development

  Innovation Pharma Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase II Results and Increased Brilacidin Franchise Value

  Innovation Pharma today is pleased to provide an update on the developmental plan for Brilacidin, its first-in-class defensin-mimetic drug candidate, for the prevention and treatment of Oral Mucositis.

  December 18, 2017

   · 

  9 min read
• EDAP’s Focal One Robotic HIFU Treatments Performed at Acibadem Hospital, Istanbul, Turkey

  EDAP TMS S.A. (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first HIFU treatments performed at Acibadem Hospital, Istanbul, Turkey, using the Company’s Focal One Robotic HIFU device.

  December 18, 2017

   · 

  3 min read
• Policy

  Arch Therapeutics Withdraws 510(K) With Plans to Resubmit After Further Discussions With FDA

  Arch Therapeutics today announced that the Company has withdrawn its 510(k) notification for its medical device AC5 Topical Gel, from the FDA with plans to submit a new 510(k) as soon as possible following further discussion with the FDA.

  December 18, 2017

   · 

  4 min read
• Biotech Beach

  CytomX Therapeutics Added to NASDAQ Biotechnology Index

  CytomX Therapeutics today announced that the company has been added to the NASDAQ Biotechnology Index effective December 18th, 2017.

  December 18, 2017

   · 

  1 min read
• Drug Development

  Aduro Biotech Announces the Initiation of a Phase I/II Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma

  The study is designed to evaluate the safety and activity of BION-1301, a humanized anti-APRIL antibody, for adults with relapsed or refractory multiple myeloma.

  December 18, 2017

   · 

  7 min read